Scarica l'app Stockscreener
812.25
1.56%
12.46
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$799.80
Aprire:
$802.93
Volume 24 ore:
1.19M
Relative Volume:
0.36
Capitalizzazione di mercato:
$768.44B
Reddito:
$40.86B
Utile/perdita netta:
$8.37B
Rapporto P/E:
149.88
EPS:
5.4193
Flusso di cassa netto:
$-2.28B
1 W Prestazione:
+2.91%
1M Prestazione:
-0.81%
6M Prestazione:
-2.28%
1 anno Prestazione:
+39.08%
Intervallo 1D:
$801.61
$816.20
Intervallo di 1 settimana:
$780.30
$816.20
Portata 52W:
$561.65
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Confronta LLY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
812.16 | 768.44B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
110.07 | 482.80B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
153.73 | 353.35B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
182.91 | 322.91B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
102.23 | 254.41B | 63.17B | 12.15B | 14.84B | 4.77 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Why Is Eli Lilly and Company (LLY) Among Louis Navellier’s Top Stock Picks Heading Into 2025? - Yahoo Finance
Eli Lilly and Novo Nordisk’s obesity moat just got stronger | Company Business News - Mint
Eli Lilly and Novo Nordisk’s Obesity Moat Just Got Stronger - Yahoo! Voices
Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy? - The Motley Fool
Eli Lilly & Co. stock outperforms competitors on strong trading day - MarketWatch
LLY: Eli Lilly (LLY) vs. Catalent (CTLT): Which Pharma Stock Offers Better Returns? - StockNews.com
Why Is Lilly (LLY) Down 5% Since Last Earnings Report? - Yahoo Finance
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030 - 24/7 Wall St.
Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch - MarketBeat
Down More Than 20% From Its High, Is Now the Time to Buy Eli Lilly Stock? - The Motley Fool
MHRA approves Eli Lilly’s Alzheimer’s diagnostic imaging agent Tauvid - Medical Device Network
Chief corporate brand officer Lina Polimeni on Eli Lilly’s ‘big evolution’ in marketing - Campaign US
Why Amgen's Weight Loss Result Is a Win for Eli Lilly - The Motley Fool
Eli Lilly Stock Pops After Biden Proposes Medicare Cover Obesity Drugs. Is LLY Stock A Buy? - Investor's Business Daily
Eli Lilly Stock Climbs 5% as White House Backs Medicare Obesity Drug Proposal - Yahoo Finance
Eli Lilly shares jump on two big updates and Jim Cramer is so here for it - CNBC
Eli Lilly, Novo Nordisk Stocks Gain as Biden Moves to Expand Coverage of Weight-Loss Drugs - Yahoo Finance
Novo, Lilly shares rise as Biden proposes obesity care coverage - Reuters
Eli Lilly, Amazon lead market cap stock movers on Tuesday - Investing.com
Novo Nordisk, Eli Lilly shares up as Biden proposes obesity coverage - Yahoo Finance
Sanofi joins J&J, Eli Lilly in proposing 340B rebate model - Healthcare Dive
Eli Lilly Stock Is Rising Tuesday: What's Going On? - Benzinga
Eli Lilly & Co. (LLY) and Novo Nordisk (NVO) gain on Biden's GLP-1 proposal - StreetInsider.com
Pfizer led industrywide sales surge in Q3 after several quarters of dominance by Eli Lilly, Novo Nordisk - FiercePharma
Eli Lilly’s (LLY) Breakthroughs: Hedge Funds’ New Healthcare Favorite - Yahoo Finance
Jim Cramer on Eli Lilly and Company (LLY): ‘It’s Valuable’ - Insider Monkey
Eli Lilly Stock Price | LLY Stock Quote, News, and History - Markets Insider
Goldman Sachs: Eli Lilly and Company (LLY) Is A Top Growth Investor Stock - Yahoo Finance
Healthcare Stocks Got Crushed After the Election—Is It Time to Buy? - Morningstar
ELI LILLY AND COMPANY (LLY) - MSN
Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs - Benzinga
Kisunla From Eli Lilly - Pharmacy Times
Is Now a Good Time to Buy the Dip in Eli Lilly Stock? - The Motley Fool
Eli Lilly, Verge announce milestones in ALS collaboration - Yahoo Finance
Eli Lilly Teams With Laekna For Innovative Obesity Treatment - Finimize
Jim Cramer on Eli Lilly and Company (LLY): ‘I’m Kind Of Blown Away’ - Insider Monkey
China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug - Reuters
Oceanside Unified takes on Eli Lilly and CVS Caremark in insulin pricing lawsuit - CBS News 8
Eli Lilly and China-based biotech Laekna team on obesity drug - TipRanks
Eli Lilly in pact with Chinese biotech for novel weight loss therapy - Seeking Alpha
UnitedHealth, Eli Lilly Lead Market Cap Stock Movers on Wednesday By Investing.com - Investing.com Australia
UnitedHealth, Eli Lilly Lead Market Cap Stock Movers on Wednesday - Investing.com
Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity - BioSpace
Lilly to develop ALS therapeutics against targets identified under Verge collaboration - BioWorld Online
Is It Time to Sell Eli Lilly and Pfizer Stocks? - The Motley Fool
The Zacks Analyst Blog Highlights Eli Lilly, PepsiCo and Morgan Stanley - Yahoo Finance
Eli Lilly: Procter & Gamble CEO joins board - Marketscreener.com
Eli Lilly and Company (LLY) Announces Board Changes: Jon Moeller Joins, Karen Walker Resigns - GuruFocus.com
Eli Lilly & Co Appoints Procter & Gamble CEO to Board - TipRanks
Eli Lilly appoints Jon Moeller to board of directors - TipRanks
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.29%
0.78%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):